Neurogene Inc.
No SEC Form 4 filings for $NGNE in the last 30 days.
See all $NGNE insider activity →HC Wainwright & Co. reiterated a Buy rating on Neurogene with a $65 price target, implying a 140.8% upside from the Oct 27 close of $26.99. Analysts highlight NGN-401's strong competitive positioning and positive clinical efficacy signals in treating Rett syndrome.
Neurogene Inc. (NGNE) shared preclinical data for NGN-401 in Rett syndrome at ESGCT, noting rapid ssAAV expression and support for ICV delivery. The data reinforce the therapy's design but are not clinical trial results.
JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning NGNE (Neurogene Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent NGNE coverage spans financial news, earnings and corporate actions.
Analyst reiteration with a high upside target reinforces bullish expectations around NGN-401’s Rett syndrome program, potentially supporting near-term sentiment.
The preclinical results reinforce the therapeutic design and may improve market perception of NGNE's pipeline.
Analyst initiation and a high price target suggest strong upside potential.
Analyst target reduction plus dilution context may pressure near-term sentiment, but the maintained Buy and extended runway support the bull case.
The filing is primarily a corporate presentation with forward-looking commercialization and development plans for NGN-401, offering limited new, decision-grade datapoints in the provided text.
AlphAI scores every news story that mentions NGNE with an AI model for sentiment and relevance, and aggregates insider trades from Neurogene Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HC Wainwright & Co. reiterated a Buy rating on Neurogene with a $65 price target, implying a 140.8% upside from the Oct 27 close of $26.99. Analysts highlight NGN-401's strong competitive positioning and positive clinical efficacy signals in treating Rett syndrome.
2 min readNeurogene Inc. (NGNE) shared preclinical data for NGN-401 in Rett syndrome at ESGCT, noting rapid ssAAV expression and support for ICV delivery. The data reinforce the therapy's design but are not clinical trial results.
1 min readJPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.
2 min readH.C. Wainwright cut its Neurogene (NASDAQ:NGNE) price target to $65 from $70 but kept a Buy rating. The firm cited Neurogene’s Process Performance Qualification campaign, expected to finish by year-end 2026, and a recent follow-on offering raising about $144 million gross and $134.8 million net. Pro forma cash is about $360.2 million, extending runway into Q1 2029.
4 min readNeurogene Inc. (NGNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participan
3 min readNeurogene Inc. (NGNE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 ngne-june2026cmpoxunderwri.htm EX-1.1 Document NEUROGENE INC. (a Delaware corporation) 3,500,000 Shares of Common Stock Pre-Funded Warrants to purchase up to 666,666 shares of Common Stock UNDERWRITING AGREEMENT June 30, 2026 Leerink Partners LLC Stifel, Nicolaus & Compa
3 min read
